Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005;7(4):155-61.
doi: 10.4088/pcc.v07n0403.

Treating patients with moderate to severe Alzheimer's disease: implications of recent pharmacologic studies

Concetta M Forchetti  1
Affiliations

Treating patients with moderate to severe Alzheimer's disease: implications of recent pharmacologic studies

Concetta M Forchetti. Prim Care Companion J Clin Psychiatry. 2005.

Abstract

Background and objective: As the prevalence of Alzheimer's disease (AD) continues to rise, physicians will be challenged to manage increasing numbers of patients with moderate to severe AD. Despite the need for active treatment and management, the growing AD population has been overlooked in the primary care setting. Currently, the approved treatments for AD are the cholinesterase inhibitors donepezil, riva-stigmine, and galantamine and the N-methyl-D-aspartate receptor antagonist memantine. The objective of this article is to review recent pharmacologic studies and discuss implications for treatment of moderate to severe AD.

Data sources and study selection: A PubMed search was performed for publications from 1995 to 2004 using the search terms moderate or severe, efficacy, and Alzheimer. The search was limited to randomized, controlled trials published in English. The search was further restricted to prospective studies of pharmacologic agents that included patients with severe dementia (Mini-Mental State Examination score < 10). A total of 96 citations were retrieved. Of these, 5 met the inclusion criteria.

Data extraction and synthesis: Randomized, double-blind, placebo-controlled studies in patients with moderate to severe AD have been conducted for donepezil and memantine. Patients treated with donepezil monotherapy showed improved cognition, stabilized function, and improved behavioral symptoms. Patients treated with memantine monotherapy showed less than expected decline in cognition, function, and behavioral symptoms. Patients who received memantine treatment adjunctive to stable, long-term donepezil treatment derived cognitive, functional, and behavioral benefits from add-on therapy.

Conclusion: Overall, published studies of donepezil and memantine report treatment benefits.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Stages of Alzheimer's Disease Symptoms as Defined by the Mini-Mental State Examinationa
See this image and copyright information in PMC

References

    1. Ernst RL, Hay JW. Economic research on Alzheimer disease: a review of the literature. Alzheimer Dis Assoc Disord. 1997 11suppl 6. 135–145. - PubMed
    1. Kirschstein R. Disease-specific estimates of direct and indirect costs of illness and NIH support. Fiscal year 2000 update. Department of Health and Human Services, National Institutes of Health. Available at: http://ospp.od.nih.gov/ecostudies/COIreportweb.htm. Accessed October 31, 2002.
    1. United States General Accounting Office. Report to the Secretary of Health and Human Services. Alzheimer's Disease: Estimates of Prevalence in the United States. Washington, DC: US General Accounting Office. 1998
    1. Evans DA, Funkenstein HH, and Albert MS. et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA. 1989 262:2551–2556. - PubMed
    1. Katzman R, Fox PJ. The world-wide impact of dementia: projections of prevalence and costs. In: Mayeux R, Christen Y, eds. Epidemiology of Alzheimer's Disease: From Gene to Prevention. Heidelberg, Germany: Springer-Verlag. 1999 1–17.